Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review.

IF 5.5 3区医学 Q1 CLINICAL NEUROLOGY

Journal of Psychopharmacology Pub Date : 2025-10-01 DOI:10.1177/02698811251375895

Adele Ravelli, Chiara Ceolin, Mario Virgilio Papa, Margherita Vergadoro, Maria Devita, Marina De Rui, Paolo Simioni, Giuseppe Sergi, Alessandra Coin

{"title":"Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review.","authors":"Adele Ravelli, Chiara Ceolin, Mario Virgilio Papa, Margherita Vergadoro, Maria Devita, Marina De Rui, Paolo Simioni, Giuseppe Sergi, Alessandra Coin","doi":"10.1177/02698811251375895","DOIUrl":null,"url":null,"abstract":"Background: Behavioral and psychological symptoms of dementia (BPSD) affect patients' and caregivers' well-being. Cannabinoids may offer a promising therapeutic option for managing BPSD.Aims: This systematic review aims to explore the strengths of using this class of substances in the context of dementia care.Methods: We conducted a comprehensive search across Embase Ovid, PubMed, Cochrane Library, APA PsycInfo, and Web of Science, identifying 1839 studies, with 14 selected for full review. Quality was assessed using the Newcastle-Ottawa and the modified Jadad Scales.Results/outcomes: Ten studies (278 participants) were finally included. They showed cannabinoids helped reduce agitation and nocturnal disturbances.Conclusions/interpretation: In conclusion, cannabinoids show promise in managing BPSD in dementia, with good tolerability and safety. Further studies could solidify these findings.","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"2698811251375895"},"PeriodicalIF":5.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811251375895","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Behavioral and psychological symptoms of dementia (BPSD) affect patients' and caregivers' well-being. Cannabinoids may offer a promising therapeutic option for managing BPSD.

Aims: This systematic review aims to explore the strengths of using this class of substances in the context of dementia care.

Methods: We conducted a comprehensive search across Embase Ovid, PubMed, Cochrane Library, APA PsycInfo, and Web of Science, identifying 1839 studies, with 14 selected for full review. Quality was assessed using the Newcastle-Ottawa and the modified Jadad Scales.

Results/outcomes: Ten studies (278 participants) were finally included. They showed cannabinoids helped reduce agitation and nocturnal disturbances.

Conclusions/interpretation: In conclusion, cannabinoids show promise in managing BPSD in dementia, with good tolerability and safety. Further studies could solidify these findings.

查看原文本刊更多论文

大麻素能缓解老年痴呆患者的行为症状吗？系统回顾。

背景：痴呆症（BPSD）的行为和心理症状影响患者和照顾者的幸福感。大麻素可能为治疗BPSD提供了一个有希望的治疗选择。目的：本系统综述旨在探讨在痴呆症护理中使用这类物质的优势。方法：我们对Embase Ovid、PubMed、Cochrane Library、APA PsycInfo和Web of Science进行了全面的检索，确定了1839项研究，其中14项被选中进行全面审查。使用纽卡斯尔-渥太华量表和修改后的Jadad量表评估质量。结果/结局：最终纳入10项研究（278名受试者）。他们发现大麻素有助于减少躁动和夜间干扰。结论/解释：总之，大麻素具有良好的耐受性和安全性，有望治疗痴呆患者的BPSD。进一步的研究可以巩固这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Psychopharmacology 医学-精神病学

CiteScore

8.60

自引率

4.90%

发文量

126

审稿时长

3-8 weeks

期刊介绍： The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.